Switzerland

News from aidsmap

• T-20 expanded access study announced

  Anna Poppa | 07 November 2001

  Roche have announced plans for widening access to their experimental fusion inhibitor, T-20 (pentafuside), a new type of anti-HIV treatment. A worldwide open-label safety study, codenamed T-20 305, is ...

• HAART for $125 a year: how can it be done?

  Keith Alcorn | 31 October 2001

  It may be possible to reduce the cost of HAART for developing countries to less than $125 a year if research into dosing and intermittent treatment can be funded, according to Dr Andrew ...

• Treating high cholesterol in HAART patients

  Keith Alcorn | 29 October 2001

  Controversy over the risk of heart disease in people on HAART continued at the Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Infection last week, with competing ...

• UK doubles commitment to Global Fund

  Finance and funding
  Julian Meldrum | 26 June 2001

  The UK's Secretary of State for International Development, the Rt Hon Clare Short MP, announced at the UN General Assembly in New York on Monday 25 September that the UK ...

• Drug access table: June 2001 update

  Keith Alcorn | 20 June 2001

  This table updates an edition published in April to include new data on prices and discounts offered by several Indian manufacturers of generic antiretrovirals, with the brand names of their ...

• Global drug prices: what is on offer today?

  Keith Alcorn | 20 April 2001

  This table summarises the latest information provided by companies regarding the prices at which they are currently offering antiretrovirals to resource-poor countries, and the terms of the offers. Some of these ...

• HIV risk from single contact may be higher than thought

  Keith Alcorn | 05 March 2001

  The risk of HIV transmission from activities like unprotected anal intercourse with new partners may be dangerously underestimated by long-term studies of serodiscordant partners, a leading researcher into the sexual ...

• Hydroxyurea debate revives: suitable drug for poor nations?

  Megan Nicholson | 05 March 2001

  The debate over the use of hydroxyurea plus ddI in the treatment of HIV disease has been revived at the World AIDS Conference, despite a study which showed that hydroxyurea ...